Lee Gravatt Wilke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Lee Gravatt Wilke has a total of 179 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer A. Mirrielees
Department of Surgery, Clinical Science Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
5 shared publications - Jenny E. Gumperz
Department of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
4 shared publications Jill D. Haag
4 shared publicationsMichael N. Gould
4 shared publications- Nicholas A. Zumwalde
Department of Medical Microbiology and Immunology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53706; and
4 shared publications - Stephanie M. McGregor
Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA
4 shared publications
Latest Publications
- 10 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
Phase 1b breast cancer prevention clinical trial of 9cUAB30 administered prior to surgical resection
We performed a phase Ib clinical trial in participants with breast carcinoma evaluating the effects of the novel rexinoid 9cUAB30 orally for 14-28 days prior to surgical resection. Twenty-seven female volunteers (mean±S.D. age 63±10 years) newly diagnosed with breast cancer awaiting surgery as their initial treatment received 9cUAB30 once daily (240 mg for first 5 participants and 160 mg for the subsequent 22 participants) for 13-25 days. Comparison of breast tissue proliferation (Ki-67) at baseline and end of study revealed no significant change with results similar to participant-matched historical control samples. Secondary analysis of tissue apoptosis (Cleaved Caspase 3) observed an increase from baseline to end of study but when compared to changes exhibited by matched to historical controls, no difference was observed. Exploratory analysis of participant tissue samples by nCounter molecular profiling observed increased cytokine and decreased proliferation marker gene expression. Assessment of circulating dendritic cells demonstrated an increase in type 1 monocytic and a decrease in type 2 plasmacytic cells. 9cUAB30 plasma concentrations day of surgery were 349 ± 204 ng/ml (range 66-873). Most participants had grade 1-2 adverse events with the most common being hypertension, headache and gastrointestinal- and skin-related symptoms. Laboratory analysis observed a small but significant increase in total and LDL serum cholesterol (p<0.001). In this phase Ib clinical trial, 9cUAB30 was well tolerated with mild rexinoid-related side effects, no measurable effect upon breast tissue proliferation but encouraging exploratory effects on gene expression and circulating immune effector cells at relatively high daily rexinoid dosing.
- 10 November 2026
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
Phase 1b breast cancer prevention clinical trial of 9cUAB30 administered prior to surgical resection
We performed a phase Ib clinical trial in participants with breast carcinoma evaluating the effects of the novel rexinoid 9cUAB30 orally for 14-28 days prior to surgical resection. Twenty-seven female volunteers (mean±S.D. age 63±10 years) newly diagnosed with breast cancer awaiting surgery as their initial treatment received 9cUAB30 once daily (240 mg for first 5 participants and 160 mg for the subsequent 22 participants) for 13-25 days. Comparison of breast tissue proliferation (Ki-67) at baseline and end of study revealed no significant change with results similar to participant-matched historical control samples. Secondary analysis of tissue apoptosis (Cleaved Caspase 3) observed an increase from baseline to end of study but when compared to changes exhibited by matched to historical controls, no difference was observed. Exploratory analysis of participant tissue samples by nCounter molecular profiling observed increased cytokine and decreased proliferation marker gene expression. Assessment of circulating dendritic cells demonstrated an increase in type 1 monocytic and a decrease in type 2 plasmacytic cells. 9cUAB30 plasma concentrations day of surgery were 349 ± 204 ng/ml (range 66-873). Most participants had grade 1-2 adverse events with the most common being hypertension, headache and gastrointestinal- and skin-related symptoms. Laboratory analysis observed a small but significant increase in total and LDL serum cholesterol (p<0.001). In this phase Ib clinical trial, 9cUAB30 was well tolerated with mild rexinoid-related side effects, no measurable effect upon breast tissue proliferation but encouraging exploratory effects on gene expression and circulating immune effector cells at relatively high daily rexinoid dosing.
- 24 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (7) , OP2500073-1285
Benchmarking the Current Landscape: Insights From an Association of American Cancer Institutes Survey on Academic Cancer Service Lines
PURPOSE: A cancer service line (CSL) in academic medical centers provides a patient-centered approach aimed at enhancing the patient experience and clinical outcomes, managing financial operations, increasing access to clinical research, and reducing health disparities. In 2023, the Association of American Cancer Institutes (AACI) Physician Clinical Leadership Initiative (PCLI) Steering Committee conducted a survey to evaluate the current state of CSLs with respect to governance, leadership, organizational, and financial structure and function. METHODS: The survey was electronically sent to cancer center directors and administrative directors at 107 of AACI's 108-member cancer centers, achieving a response rate of 70%. Survey participation was voluntary, and no compensation was provided. RESULTS: Fifty-eight (77%) of the 75 survey respondents (which included 40 National Cancer Institute–designated cancer centers) had a defined CSL with only 35 (60%) using a formal charter. All CSL leadership teams included physician leaders, and 44 (76%) centers included their cancer center director within this leadership. More than 28 key services were identified as parts of the CSL structures. Most respondents reported that strategic planning (88%), quality and safety (83%), and regional alignment (78%) were key responsibilities. Twenty-six (45%) centers reported a policy defining a funds flow from the health system to the cancer center. Performance assessment for the CSLs included metrics related to growth and finance, access and services, quality and outcomes, and academics. CONCLUSION: These results demonstrate the diverse nature of CSLs across academic medical systems within the United States. Furthermore, given the complexity faced by academic cancer centers in establishing and expanding their CSLs, AACI remains committed to working closely with its members to identify best practices focused on innovative and value-based cancer care.
- 24 September 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- Vol. 22 (7) , OP2500073-1285
Benchmarking the Current Landscape: Insights From an Association of American Cancer Institutes Survey on Academic Cancer Service Lines
PURPOSE: A cancer service line (CSL) in academic medical centers provides a patient-centered approach aimed at enhancing the patient experience and clinical outcomes, managing financial operations, increasing access to clinical research, and reducing health disparities. In 2023, the Association of American Cancer Institutes (AACI) Physician Clinical Leadership Initiative (PCLI) Steering Committee conducted a survey to evaluate the current state of CSLs with respect to governance, leadership, organizational, and financial structure and function. METHODS: The survey was electronically sent to cancer center directors and administrative directors at 107 of AACI's 108-member cancer centers, achieving a response rate of 70%. Survey participation was voluntary, and no compensation was provided. RESULTS: Fifty-eight (77%) of the 75 survey respondents (which included 40 National Cancer Institute–designated cancer centers) had a defined CSL with only 35 (60%) using a formal charter. All CSL leadership teams included physician leaders, and 44 (76%) centers included their cancer center director within this leadership. More than 28 key services were identified as parts of the CSL structures. Most respondents reported that strategic planning (88%), quality and safety (83%), and regional alignment (78%) were key responsibilities. Twenty-six (45%) centers reported a policy defining a funds flow from the health system to the cancer center. Performance assessment for the CSLs included metrics related to growth and finance, access and services, quality and outcomes, and academics. CONCLUSION: These results demonstrate the diverse nature of CSLs across academic medical systems within the United States. Furthermore, given the complexity faced by academic cancer centers in establishing and expanding their CSLs, AACI remains committed to working closely with its members to identify best practices focused on innovative and value-based cancer care.
- 13 June 2025
- Published by Elsevier in Advances in Surgery
- Vol. 59 (1) , 1-14
Evolution in the Management of Axillary Lymph Nodes in Breast Cancer
- 13 June 2025
- Published by Elsevier in Advances in Surgery
- Vol. 59 (1) , 1-14
Evolution in the Management of Axillary Lymph Nodes in Breast Cancer
Cancer registries: A look back and forward
As electronic health records and detailed digital health data are standardized and become more accessible with associated privacy support, cancer registries both nationally and worldwide will also continue to improve and provide rich resources for epidemiologic, health services, and outcomes research.
Cancer registries: A look back and forward
As electronic health records and detailed digital health data are standardized and become more accessible with associated privacy support, cancer registries both nationally and worldwide will also continue to improve and provide rich resources for epidemiologic, health services, and outcomes research.